(Q34218627)

31 July 2017

1 reference

title

Vaccines in the 21st century. (English)

1 reference

31 July 2017

1

Plotkin SA

1 reference

31 July 2017

publication date

1 March 2001

1 reference

Infectious Disease Clinics of North America

31 July 2017

published in

1 reference

31 July 2017

volume

15

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

307-327

1 reference

A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

A high degree of natural immunologic priming to the capsular polysaccharide may not prevent Haemophilus influenzae type b meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Uptake and transport of copolymer biodegradable microspheres by rabbit Peyer's patch M cells

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

The promise of proteomics

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : II. IMMUNOLOGICAL SPECIFICITY OF SYNTHETIC SUGAR-PROTEIN ANTIGENS.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Protection against mycoplasma infection using expression-library immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Proteomics: quantitative and physical mapping of cellular proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Insertion of the fusion gene from Newcastle disease virus into a non-essential region in the terminal repeats of fowlpox virus and demonstration of protective immunity induced by the recombinant

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

From the World Health Organization. Development of dengue and Japanese encephalitis vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Exploring the new world of the genome with DNA microarrays

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Immunisation with canarypox virus expressing rabies glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Rotavirus vaccine administered parenterally induces protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Induction and assessment of immunity at enteromucosal surfaces in humans: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Prevention of type 1 diabetes from laboratory to public health

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Specific immune response in humans following rectal delivery of live typhoid vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Efficacy of a therapeutic cocaine vaccine in rodent models.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Oral immunization with a recombinant bacterial antigen produced in transgenic plants.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Herpes simplex virus turns off the TAP to evade host immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Toward HIV eradication or remission: the tasks ahead

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

The prevention of type I diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

The outer surface protein A (OspA) of Borrelia burgdorferi: a vaccine candidate and bioactive mediator

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Progress in the development of an HIV-1 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Effect of neonatal immunization with diphtheria and tetanus toxoids on antibody responses to Haemophilus influenzae type b conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Immunization against rabies with plant-derived antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Vaccination to prevent persistent viral infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

1 reference

7 January 2021

Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Orally administered microencapsulated reovirus can bypass suckled, neutralizing maternal antibody that inhibits active immunization of neonates

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Poxvirus-based vectors as vaccine candidates

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

The acellular pertussis vaccine trials: an interpretation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Acellular vaccine efficacy trials

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Developed countries should use inactivated polio vaccine for the prevention of poliomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Vaccination against the major infectious diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Vaccination against cytomegalovirus, the changeling demon

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

The development of cowpea mosaic virus as a potential source of novel vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Active immunization with pC protein ofBorrelia burgdorferi protects gerbils againstB. burgdorferi infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Alphaviruses--vectors for the expression of heterologous genes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Vaccines for bacterial sexually transmitted infections: a realistic goal?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Herpes simplex virus vaccines as immunotherapeutic agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Immunization of Macaca mulatta with aroA attenuated Salmonella typhimurium expressing the SIVp27 antigen.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Vaccines for control of fertility and hormone-dependent cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Immunogenicity of transgenic plant-derived hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Alphavirus expression vectors and their use as recombinant vaccines: a minireview.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Synthesis and assembly of hepatitis B virus surface antigen particles in yeast

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Lack of correlation between serum rotavirus antibody titers and protection following vaccination with reassortant RRV vaccines. US Rotavirus Vaccine Efficacy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Adhesins as targets for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Direct gene transfer into mouse muscle in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b-PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

Self-replicating Semliki Forest virus RNA as recombinant vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970280-4

7 January 2021

10.1016/S0891-5520(05)70280-4

Identifiers

DOI

1 reference

31 July 2017

1 reference